

Patient Information

Name: NameFirst NameLast

DOB: 1990.12.07 **Gender:** M

Promis Diagnostics

1 Post, Suite 100, Irvine, CA 92618 Laboratory Director: Safedin Sajo Beqaj, PhD, HCLD, CC (ABR)

Clinical Molecular Pathology Supervisor: Dr. Bo Ram Bang, PhD.

CLIA#: 05D2185450 CAP#: 879466501

Specimen Information

Accession Number: BCTEST-003
Date Collected: 2023.12.04
Date Received: 2023.12.05
Report Date: 2023.12.05

Sample Type: Urine

EarlyTect® Bladder Cancer Detection Test Report

Physician Information

Facility Name: Promis Dx

Provider Name: PROMIS DIAGNOSTICS, INC. **Address:** 1 Post, Suite 100 - Suite 100 - Irvine

California

EarlyTect® Bladder Cancer Detection Test

Test	Results	Normal Reference Range
PENK DNA methylation	Positive**	Negative

Result Interpretation:

*A negative result indicates a lower risk of bladder cancer or no bladder cancer. However, a negative EarlyTect® Bladder Cancer Detection (EarlyTect® BCD) test result does not guarantee absence of cancer. Patients with a negative EarlyTect® BCD test result should be advised to continue participating in a recommended bladder cancer screening program according to screening guidelines.

**A positive result indicates a higher probability of bladder cancer. A positive result is not confirmatory evidence for bladder cancer. Patients with a positive EarlyTect® BCD test result should be referred for diagnostic cystoscopy.

Test Description:

The EarlyTect® BCD is a proprietary in vitro genetic test designed to detect the presence of bladder cancer by analyzing urine DNA for patients through qualitative analysis of a single epigenetic biomarker gene DNA methylation (methylated PENK DNA). The EarlyTect® BCD is for use with a methylation-specific real-time PCR detection system coupled with linear target enrichment step (LTE-qMSP) after DNA extraction and bisulfite conversion. It detects both methylated PENK and an internal control gene.

This test confirmed that patients with hematuria can be diagnosed with 85.7% accuracy for all stages bladder cancer and 90% accuracy for Ta high grade and higher stages bladder cancer in clinical trials^{1,2}.

Limitation:

Improper specimen collection techniques, storage, or shipment protocols may cause unreliable results.

An absence of detection does not imply the absence of bladder cancer or does not exclude the possibility that the target sequence is present below the limit of detection. The EarlyTect® BCD report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.

Disclaimer: This test is lab developed test and its performance characteristics determined by Promis Dx. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes and should not be regarded as investigational or for research. The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 as qualified to perform high complexity clinical testing and is accredited by the College of American Pathologists (CAP).







References: 1. Oh TJ, et al. J Mol Diagn. 2023, 2. Oh TJ, et al. BMC Cancer. 2022.

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

Patient: NameFirst NameLast Accession: BCTEST-003 Page 1 of 2

Comment: None Admin: Electronically signed and dated on 2023.12.05 15:45 Dr. Bo Ram Bang

This report, associated with order #BCTEST-003, has been approved by the following reviewers:

References: 1. Oh TJ, et al. J Mol Diagn. 2023, 2. Oh TJ, et al. BMC Cancer. 2022.

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

Patient: NameFirst NameLast Accession: BCTEST-003 Page 2 of 2